Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: Insights from PET and SPECT imaging

Current Pharmaceutical Design

Volumn 15, Issue 22, 2009, Pages 2550-2559

  Howes, O D ^a,b   Egerton, A ^a,b   Allan, V ^a   McGuire, P ^b   Stokes, P ^a,b   Kapur, S ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic; Etiology; Imaging; Mechanisms; PET; Psychosis; Schizophrenia; Treatment

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG RESPONSE; DYSPHORIA; HUMAN; HYPERPROLACTINEMIA; LIMBIC CORTEX; MUSCLE SPASM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM; THEORY; UNPLEASANT SENSATION;

ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE; DRUG DISCOVERY; DRUG RESISTANCE; HUMANS; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 69249145260     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788957528     Document Type: Review

References (103)

1. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al. Schizophrenia: Manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992; 20: 1-97.
2. Jablensky A. Epidemiology of schizophrenia: The global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000; 250(6): 274-285.
3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349(9063): 1436-1442.
4. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2(5): E141.
5. Hu TW. Perspectives: An international review of the national cost estimates of mental illness, 1990-2003. J Ment Health Policy Econ 2006; 9(1): 3-13.
6. Guest JF, Cookson RF. Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999; 15(6): 597-610.
7. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004; 30(2): 279-293.
8. Schultz SK, Andreasen NC. Schizophrenia. Lancet 1999; 353(9162): 1425-1430.
9. Moller HJ. Course and long-term treatment of schizophrenic psychoses. Pharmacopsychiatry 2004; 37(Suppl 2): 126-135.
10. Kempf L, Hussain N, Potash JB. Mood disorder with psychotic features, schizoaffective disorder, and schizophrenia with mood features: Trouble at the borders. Int Rev Psychiatry 2005; 17(1): 9-19.
11. Howes OD, McDonald C, Cannon M, Arseneault L, Boydell J, Murray RM. Pathways to schizophrenia: The impact of environmental factors. Int J Neuropsychopharmacol 2004; 7(Suppl 1): S7-S13.
12. Broome MR, Woolley JB, Tabraham P, Johns LC, Bramon E, Murray GK, et al. What causes the onset of psychosis? Schizophr Res 2005; 79(1): 23-34.
13. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006; 12(9): 1016-1022.
14. McGuire P, Howes OD, Stone J, Fusar-Poli P. Functional neuroimaging in schizophrenia: Diagnosis and drug discovery. Trends Pharmacol Sci 2008; 29(2): 91-98.
15. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160(1): 13-23.
16. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987; 91(4): 415-433.
17. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180(4596): 1200.
18. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192(4238): 481-483.
19. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261(5562): 717-719.
20. Matthysse S. Antipsychotic drug actions: A clue to the neuropathology of schizophrenia? Fed Proc 1973; 32(2): 200-205.
21. Snyder SH. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am J Psychiatry 1976; 133(2): 197-202.
22. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991; 148(11): 1474-1486.
23. Moore RY, Whone AL, McGowan S, Brooks DJ. Monoamine neuron innervation of the normal human brain: An 18F-DOPA PET study. Brain Res 2003; 982(2): 137-145.
24. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl 2007; 51: S13-s18.
25. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995; 346(8983): 1130-1131.
26. Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 1999; 35(1): 41-50.
27. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999; 46(5): 681-688.
28. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66(1): 13-20.
29. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998; 155(6): 761-767.
30. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de BA, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94(6): 2569-2574.
31. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93(17): 9235-9240.
32. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97(14): 8104-8109.
33. Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 2004; 55(10): 1001-1006.
34. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998; 42(3): 211-221.
35. Kestler LP, Walker E, Vega EM. Dopamine receptors in the brains of schizophrenia patients: A meta-analysis of the findings. Behav Pharmacol 2001; 12(5): 355-371.
36. Zakzanis KK, Hansen KT. Dopamine D2 densities and the schizophrenic brain. Schizophr Res 1998; 32(3): 201-206.
37. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385(6617): 634-636.
38. Karlsson P, Farde L, Halldin C, Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 2002; 159(5): 761-767.
39. Talvik M, Nordstrom AL, Okubo Y, Olsson H, Borg J, Halldin C, et al. Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 2006; 148(2-3): 165-173.
40. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006; 85(1-3): 232-244.
41. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 2002; 59(1): 25-30.
42. Takahashi H, Higuchi M, Suhara T. The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol Psychiatry 2006; 59(10): 919-928.
43. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, et al. Psychosis pathways converge via D2high dopamine receptors. Synapse 2006; 60(4): 319-346.
44. Graf-Guerrero A, Romina M, Agid O, Marcon H, Barsoum P, Rusjan P, et al. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: A clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology. 2009. In Press
45. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2005; 79(1): 59-68.
46. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III--the final common pathway. Schizophr Bull 2009; 35(3): 549-62.
47. Brucke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B, et al. Dopamine D2 receptor imaging with SPECT: Studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991; 11(2): 220-228.
48. Brucke T, Roth J, Podreka I, Strobl R, Wenger S, Asenbaum S. Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet 1992; 339(8791): 497.
49. Klemm E, Grunwald F, Kasper S, Menzel C, Broich K, Danos P, et al. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry 1996; 153(2): 183-190.
50. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: A 123I IBZM SPET (single photon emission tomography) study. Psychol Med 1993; 23(3): 791-797.
51. Volk S, Maul FD, Hor G, Schreiner M, Weppner M, Holzmann T, et al. Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia. Psychiatry Res 1994; 55(2): 111-118.
52. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: Correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl) 1989; 99(4): 463-472.
53. Farde L, Wiesel FA, Jansson P, Uppfeldt G, Wahlen A, Sedvall G. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology (Berl) 1988; 94(1): 1-7.
54. Goyer PF, Berridge MS, Morris ED, Semple WE, Compton-Toth BA, Schulz SC, et al. PET measurement of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med 1996; 37(7): 1122-1127.
55. Kapur S, Zipursky RB, Jones C, Remington GJ, Wilson AA, DaSilva J, et al. The D2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacology 1996; 15(6): 562-566.
56. Nordstrom AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992; 106(4): 433-438.
57. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33(4): 227-235.
58. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, et al. Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 1989; 46(5): 482-484.
59. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45(1): 71-76.
60. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33(4): 227-235.
61. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157(4): 514-520.
62. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, et al. Dopamine blockade and clinical response: Evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146(7): 905-908.
63. Nordstrom AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992; 106(4): 433-438.
64. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch Gen Psychiatry 2003; 60(12): 1228-1235.
65. Catafau AM, Corripio I, Perez V, Martin JC, Schotte A, Carrio I, et al. Dopamine D2 receptor occupancy by risperidone: Implications for the timing and magnitude of clinical response. Psychiatry Res 2006; 148(2-3): 175-183.
66. Tauscher J, Jones C, Remington G, Zipursky R, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol. Psychiatry 2007; (7): 317-21.
67. Uchida H, Mamo DC, Kapur S, Labelle A, Shammi CM, Mannaert EJL, et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin. Psychiatry 2008; 69(8): 1281-6.
68. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57(6): 553-559.
69. Samaha A-N, Reckless G, Seeman P, Diwan M, Nobrega JN, Kapur S. Less is more: Antipsychotic drug effects are greater with transient rather than continuous. Biol Psychiatry 2008; 64: 145-52.
70. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49(7): 538-544.
71. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33(4): 227-235.
72. Nordstrom AL, Farde L. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 1998; 18(4): 305-310.
73. Voruganti L, Awad AG. Neuroleptic dysphoria: Towards a new synthesis. Psychopharmacology (Berl) 2004; 171(2): 121-132.
74. Awad AG, Voruganti LN. Neuroleptic dysphoria: Revisiting the concept 50 years later. Acta Psychiatr Scand Suppl 2005;(427): 6-13.
75. Hollister LE. Complications from the use of tranquilizing drugs. N Engl J Med 1957; 257(4): 170-177.
76. Bressan RA, Costa DC, Jones HM, Ell PJ, Pilowsky LS. Typical antipsychotic drugs -- D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002; 56(1-2): 31-36.
77. de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 2000; 157(6): 1019-1020.
78. de HL, Lavalaye J, van BM, van NL, Booij J, van AT, et al. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: Clinical implications. Can J Psychiatry 2004; 49(5): 290-296.
79. Mizrahi R, Rusjan P, Agid O, Graff A, Mamo DC, Zipursky RB, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: A PET study in schizophrenia. Am J Psychiatry 2007; 164(4): 630-637.
80. Sheitman BB, Lieberman JA. The natural history and pathophysiology of treatment resistant schizophrenia. J Psychiatr Res 1998; 32(3-4): 143-150.
81. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45(9): 789-796.
82. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview. Br J Psychiatry Suppl 1992;(17): 41-45.
83. Grunder G, Landvogt C, Vernaleken I, Buchholz HG, Ondracek J, Siessmeier T, et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 2006; 31(5): 1027-1035.
84. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006; 31(9): 1991-2001.
85. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW. Limbic selectivity of clozapine. Lancet 1997; 350(9076): 490-491.
86. Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J, et al. A PET-study of 11CFLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl) 1997; 133(4): 396-404.
87. Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L. No support for regional selectivity in clozapine-treated patients: A PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry 2001; 158(6): 926-930.
88. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc'H C, Maziere B, et al. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001; 179: 503-508.
89. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'H C, 'et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001; 21(2): 207-214.
90. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia. Neuropsychopharmacology 2007; 32(6): 1209-1215.
91. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Am J Psychiatry 1995; 152(10): 1444-1449.
92. Trichard C, Paillere-Martinot ML, ttar-Levy D, Recassens C, Monnet F, Martinot JL. Binding of antipsychotic drugs to cortical 5-HT2A receptors: A PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 1998; 155(4): 505-508.
93. Gefvert O, Lundberg T, Wieselgren IM, Bergstrom M, Langstrom B, Wiesel F, et al. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: A PET study. Eur Neuropsychopharmacol 2001; 11(2): 105-110.
94. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004; 161(5): 818-825.
95. Travis MJ, Busatto GF, Pilowsky LS, Mulligan R, Acton PD, Gacinovic S, et al. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br J Psychiatry 1998; 173: 236-241.
96. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry 1998; 155(7): 921-928.
97. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156(2): 286-293.
98. Bose SK, Turkheimer FE, Howes OD, Mehta MA, Cunliffe R, Stokes PR, et al. Classification of schizophrenic patients and healthy controls using 18F fluorodopa PET imaging. Schizophr Res 2008; 106(2-3): 148-55.
99. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med 2007; 13(9): 1102-1107.
100. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry 2007; 51: 13-18.
101. Gur A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: New concepts in treatment. Curr Pharm Des 2008; 14(13): 1274-94.
102. Pickar D, Vinik J, Bartko JJ. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS ONE 2008; 3(9): E3150.
103. Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: Current therapeutic approach. Curr Pharm Des 2008; 14(13): 1261-9.